IL17A and COVID-19: Because of the controversial literature data regarding the connection between immunomodulatory therapies and vaccination, we intended to find serological evidence for the potentially impaired anti-COVID-19 vaccine efficacy, using follow-up samples from patients treated with anti-IL-17A and anti-TNF-α therapies.